Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Bladder cancer.

Suzanne E Patton1, M Craig Hall, Haluk Ozen

  • 1Comprehensive Cancer Center, Wake Forest University School of Medicine, Winston-Salem, North Carolina 27157, USA. spatton@wfubmc.edu

Current Opinion in Oncology
|May 1, 2002
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Oncological Outcomes of Chromophobe Versus Clear Cell Renal Cell Carcinoma: Results from A Contemporary Turkish Patient Cohort.

Urology journal·2024
Same author

Oncological outcomes of papillary <i>versus</i> clear cell renal cell carcinoma in pT1 and pT2 stage: Results from a contemporary Turkish patient cohort.

Archivio italiano di urologia, andrologia : organo ufficiale [di] Societa italiana di ecografia urologica e nefrologica·2023
Same author

Re: The Natural History of Untreated Biopsy Grade Group Progression and Delayed Definitive Treatment for Men on Active Surveillance for Early-stage Prostate Cancer.

European urology·2022
Same author

Impact of Variant Histology on Clinical and Pathological Outcomes in Patients with the Upper Urinary Tract Urothelial Carcinoma.

Sisli Etfal Hastanesi tip bulteni·2022
Same author

Should Targeted Biopsy be Performed in Patients Who Have Only Pi-rads 3 Lesions?

Archivos espanoles de urologia·2022
Same author

Re: Development and Validation of a Clinical Prognostic Stage Group System for Nonmetastatic Prostate Cancer Using Disease-specific Mortality Results from the International Staging Collaboration for Cancer of the Prostate.

European urology·2022
Same journal

Artificial intelligence-augmented robotic surgery in gynecologic oncology: intraoperative assistance and analytics.

Current opinion in oncology·2026
Same journal

Artificial intelligence in cervical cancer screening and triage: a role-stratified systematic review and bivariate meta-analysis.

Current opinion in oncology·2026
Same journal

Deep learning assisting the surgical management of gynecologic cancers.

Current opinion in oncology·2026
Same journal

Pain management in pancreatic cancer: time to change our strategy!

Current opinion in oncology·2026
Same journal

Systemic radionuclide treatments in gastro-entero-pancreatic neuroendocrine tumours.

Current opinion in oncology·2026
Same journal

5-Fluorouracil at seventy: still attractive but barely understood. A cautionary tale for drug development.

Current opinion in oncology·2026
See all related articles

Reducing carcinogen exposure and exploring chemoprevention can lower bladder cancer incidence. Promising screening tests like survivin are emerging, while advancements in surgery and chemotherapy offer improved survival rates for patients.

Area of Science:

  • Urology
  • Oncology
  • Cancer Research

Background:

  • Bladder cancer is a prevalent malignancy linked to carcinogen exposure, including tobacco, arsenic, industrial dyes, and schistosomiasis.
  • Effective screening and monitoring tests are crucial for early detection and improved patient outcomes.
  • Surgical interventions and chemotherapies are continuously evolving to enhance survival and quality of life.

Purpose of the Study:

  • To review current understanding and advancements in bladder cancer management.
  • To highlight emerging diagnostic tools and therapeutic strategies.
  • To discuss the efficacy of various treatment modalities, including surgery, chemoradiation, and chemotherapy regimens.

Main Methods:

  • Review of existing literature on bladder cancer etiology, screening, and treatment.

Related Experiment Videos

  • Analysis of survival data for different stages and treatment approaches.
  • Evaluation of neoadjuvant and adjuvant chemotherapy regimens, including cisplatin-based combinations.

    • Main Results:

    • Early-stage bladder cancer shows high survival rates with appropriate treatment, but many require radical cystectomy.
    • Definitive chemoradiation offers significant survival benefits for nonoperative candidates.
    • Neoadjuvant methotrexate, vinblastine, doxorubicin, and cisplatin (MVAC) and gemcitabine-cisplatin regimens demonstrate efficacy in advanced bladder cancer, with gemcitabine-cisplatin showing less toxicity.

    Conclusions:

    • Bladder cancer management involves a multi-faceted approach including risk reduction, screening, and tailored therapies.
    • Advancements in chemotherapy, such as gemcitabine-cisplatin, are improving outcomes with reduced toxicity.
    • Ongoing research into novel agents and treatment combinations continues to refine bladder cancer treatment strategies.